Every company experiences periods of either rapid expansion or uncontrolled growth that hinders IT’s ability to keep up with demand or scale fast enough to sustain the business. We can all admit: Change is inevitable and challenging, but with the right forewarning, leadership, and foundational planning; Companies can mitigate issues and build a stable infrastructure

Since the first major pharmaceutical breach reported in 2017 by Merck Sharp and Dohme, cyber attackers have increasingly targeted the biotech and pharmaceutical sectors. The strict regulatory compliance required in these industries creates complex digital environments, making them attractive and vulnerable targets for cyberattacks. Within a few years after the COVID-19 Pandemic, where digital transformation

Network design has always played a critical role in ensuring seamless operations in Biotech.  However data security and reliable communication are often at odds with each other.  Sites, which include laboratories, research facilities, and manufacturing plants, demand specialized network infrastructures to support their research, maintain sensitive data, and a myriad of sophisticated manufacturing equipment.  This

Hear from our Co-founder, Krisha Patel, and CEO of Cellular Origins, Edwin Stone as they discuss the current challenges in building infrastructure and capacity for cell and gene therapy in this panel hosted by Carol Houts, CSO at Germfree. ? ? Key Discussions:? The use of automation tools and robotic solutions that support scale-up activities.